From the FDA Drug Label
ADVERSE REACTIONS Most common adverse reactions in VOQUEZNA-treated patients are: Healing of Erosive Esophagitis (≥2%): gastritis, diarrhea, abdominal distension, abdominal pain, and nausea. Maintenance of Healed Erosive Esophagitis (≥3%): gastritis, abdominal pain, dyspepsia, hypertension, and urinary tract infection. Relief of Heartburn Associated with Non-Erosive Gastroesophageal Reflux Disease (≥2%): abdominal pain, constipation, diarrhea, nausea, and urinary tract infection. Treatment of H. pylori Infection (≥2%): diarrhea, dysgeusia, vulvovaginal candidiasis, abdominal pain, headache, hypertension, and nasopharyngitis. To report SUSPECTED ADVERSE REACTIONS, contact Phathom Pharmaceuticals, Inc. at toll-free phone 1-888-775-7428 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
The most common side effects of VOQUEZNA include:
- Gastritis
- Diarrhea
- Abdominal pain
- Nausea
- Urinary tract infection
- Dyspepsia
- Hypertension
- Constipation
- Dysgeusia
- Vulvovaginal candidiasis
- Headache
- Nasopharyngitis 1 1 1
From the Research
Voquezna (vonoprazan) can cause several side effects, with the most common being abdominal pain, constipation, diarrhea, nausea, and dyspepsia, as reported in the most recent study 2. The side effects of Voquezna (vonoprazan) are generally well tolerated, with the majority of patients experiencing mild to moderate adverse events.
- The most common side effects include:
- Abdominal pain
- Constipation
- Diarrhea
- Nausea
- Dyspepsia These side effects are similar to those experienced with traditional proton pump inhibitors (PPIs), but vonoprazan has been shown to have a better pharmacological profile, with a rapid onset of action and longer lasting acid suppression 3. It's essential to note that the side effect profile may vary depending on whether Voquezna is taken alone or as part of a combination therapy for H. pylori eradication 4. In general, vonoprazan is considered safe and effective for the treatment of acid-related diseases, including erosive esophagitis, gastroesophageal reflux disease (GERD), and H. pylori infections 5. However, as with any medication, it's crucial to monitor patients for any adverse events and adjust treatment accordingly. The most recent and highest quality study 2 suggests that vonoprazan is a valuable addition to the therapies available for adults with erosive esophagitis and non-erosive GERD, with a favorable safety and tolerability profile.